多发性骨髓瘤诊治进展 ——写在2019年伊始

doi:10.6040/j.issn.1671-7554.0.2019.362

摘要/Abstract

摘要： 近年来,多发性骨髓瘤的诊断及治疗、疗效评估均进展迅速,新药包括新的蛋白酶体抑制剂、新的免疫调节剂、单克隆抗体以及细胞免疫治疗的出现带来了诊断标准、诊断手段以及疗效评价标准的不断更新。就目前的诊治新进展进行综述,以期指导临床。

关键词: 多发性骨髓瘤, 诊断标准, 疗效评价标准, 治疗

Abstract: The diagnosis, treatment and efficacy evaluation of multiple myeloma are progressing rapidly in recent years. Novel agents including new proteasome inhibitors, new immunomodulators, monoclonal antibodies and cellular therapy have non-stoppingly updated the diagnostic criteria, diagnostic methods and evaluation criteria. This article reviews the current progress in diagnosis and treatment of multiple myeloma in order to guide clinical practice.

Key words: Multiple myeloma, Diagnostic criteria, Evaluation criteria, Treatment

中图分类号:

R733.3

路瑾. 多发性骨髓瘤诊治进展 ——写在2019年伊始[J]. 山东大学学报 (医学版), 2019, 57(7): 40-43.

LU Jin. Advances in the diagnosis and treatment of multiple myeloma[J]. Journal of Shandong University (Health Sciences), 2019, 57(7): 40-43.

参考文献

[1] Krönke J, Udeshi ND, Narla A, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells [J]. Science, 2014,343(6168): 301-305.
[2] Lu G, Middleton RE, Sun H, et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins [J]. Science, 2014,343(6168): 305-309.
[3] Hansford BG, Silbermann R. Advanced imaging of multiple myeloma bone disease [J]. Front Endocrinol(Lausanne), 2018, 9: 436. doi: 10.3389/fendo.2018.00436.
[4] Terpos E, Ntanasis-Stathopoulos I, Dimopoulos MA. Myeloma bone disease: from biology findings to treatment approaches [J]. Blood, 2019, 133(14): 1534-1539.
[5] Milani P, Murray DL, Barnidge DR, et al. The utility of MASS-FIX to detect and monitor monoclonal proteins in the clinic [J]. Am J Hematol, 2017, 92(8): 772-779.
[6] Moore LM, Cho S, Thoren KL: MALDI-TOF mass spectrometry distinguishes daratumumab from M-proteins [J]. Clin Chim Acta, 2019, 492: 91-94. doi: 10.1016/j.cca.
[7] 宋萍, 安志明, 周小钢, 等. 血清游离轻链的检测及其在轻链型多发性骨髓瘤中的临床意义[J]. 中国实验血液学杂志, 2015, 23(5): 1357-1361. SONG Ping, AN Zhiming, ZHOU Xiaogang, et al. Test of serum free light chain and its clinical significance in light chain multiple myeloma [J]. Journal of Experimental Hematology, 2015, 23(5): 1357-1361.
[8] Dejoie T, Corre J, Caillon H, et al. Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma [J]. Blood, 2016, 128(25): 2941-2948.
[9] 王亚哲, 路瑾, 郝乐, 等. 4色与8色荧光抗体组合检测多发性骨髓瘤患者微小残留病的比较分析[J]. 中华血液学杂志, 2017, 38(4): 272-278. WANG Yazhe, LU Jin, HAO Le,et al.Comparison and analysis of minimal residual disease in multiple myeloma patients detected by 4-color and 8-color fluorescence antibody panels [J].Chinese Journal of Hematology, 2017, 38(4): 272-278.
[10] Munshi NC, Avet-Loiseau H, Rawstron AC, et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis [J]. JAMA Oncol, 2017, 3(1): 28-35.
[11] Lahuerta JJ, Paiva B, Vidriales MB, et al. Depth of response in multiple myeloma: a pooled analysis of three pethema/gem clinical trials [J]. J Clin Oncol, 2017, 35(25): 2900-2910.
[12] Durie BG, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant(SWOG S0777): a randomised, open-label, phase 3 trial [J]. Lancet, 2017, 389(10068): 519-527.
[13] Jacobus SJ, Rajkumar SV, Weiss M, et al. Randomized phase III trial of consolidation therapy with bortezomib-lenalidomide-Dexamethasone(VRd)vs bortezomib-dexamethasone(Vd)for patients with multiple myeloma who have completed a dexamethasone based induction regimen [J]. Blood Cancer J, 2016, 6(7): 448.
[14] Moreau P, Hulin C, Macro M, et al. VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial [J]. Blood, 2016, 127(21): 2569-2574.
[15] Goldschmidt H, Lokhorst HM, Mai EK, et al. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial [J]. Leukemia, 2018, 32(2): 383-390.
[16] Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma [J]. N Engl J Med, 2017, 376(14): 1311-1320.
[17] Facon T, Dimopoulos MA, Dispenzieri A, et al. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma [J]. Blood, 2018, 131(3): 301-310.
[18] 王国苗, 杨光忠, 黄仲夏, 等, 中国多发性骨髓瘤患者接受来那度胺的多中心非干预性前瞻性观察研究[J]. 中华内科杂志, 2017, 56(7): 500-506. WANG Guomiao, YANG Guangzhong, HUANG Zhongxia, et al. A prospective multi-center trial of non-interventional and observational study of lenalidomide in Chinese patients with multiple myeloma [J]. Chinese Journal of Internal Medicine, 2017, 56(7): 500-506.
[19] Lu J, Lee JH, Huang SY, et al. Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial [J]. Br J Haematol, 2017, 176(5): 743-749.
[20] Facon T. Phase 3 randomized study of daratumumab plus lenalidomide and dexamethasone(D-Rd)versus lenalidomide and dexamethasone(Rd)in patients with newly diagnosed multiple myeloma(NDMM)ineligible for transplant(MAIA)[J]. ASH abstract LBA-2, 2018.
[21] Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma [J]. N Engl J Med, 2018, 378(6): 518-528.
[22] ODonnell EK, Laubach JP, Yee AJ, et al. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma [J]. Br J Haematol, 2018, 182(2): 222-230.
[23] Jones JR, Weinhold N, Ashby C, et al. Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients[J]. Haematologica, 2019, 7. doi: 10.3324/haematol.
[24] Johnsen HE, Bogsted M, Schmitz A, et al.The myeloma stem cell concept, revisited: from phenomenology to operational terms [J]. Haematologica, 2016, 101(12): 1451-1459.
[25] Lin L, Cao L, Liu Y, et al.B7-H3 promotes multiple myeloma cell survival and proliferation by ROS-dependent activation of Src/STAT3 and c-Cbl-mediated degradation of SOCS3 [J]. Leukemia, 2018, 20. doi: 10.1038/s41375-018-0331-6.
[26] Lin L, Zhang X, Cao L, et al. Reelin promotes adhesion of multiple myeloma cells to bone marrow stromal cells via integrin beta1 signaling [J]. J Cancer, 2017, 8(12): 2212-2222.
[27] Lakshman A, Painuly U, Rajkumar SV, et al. Natural history of multiple myeloma with de novo del(17p)[J]. Blood Cancer J, 2019, 9(3): 32.
[28] Ziogas DC, Dimopoulos MA, Kastritis E. Prognostic factors for multiple myeloma in the era of novel therapies [J]. Expert Rev Hematol, 2018, 11(11): 863-879.
[29] Lagana A, Beno I, Melnekoff D, et al. Precision medicine for relapsed multiple myeloma on the basis of an integrative multiomics approach [J]. JCO Precis Oncol, 2018. doi: 10.1200/PO.18.00019.
[30] Lohr JG, Stojanov P, Carter SL, et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy [J]. Cancer Cell, 2014, 25(1): 91-101.
[31] Harding T, Baughn L, Kumar S, et al. The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies [J]. Leukemia, 2019, 33(4): 863-883.
[32] Matulis SM, Gupta VA, Neri P, et al. Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma [J]. Leukemia, 2019, 33(5): 1291-1296.
[33] Heuck CJ, Jethava Y, Khan R, et al. Inhibiting MEK in MAPK pathway-activated myeloma [J]. Leukemia, 2016, 30(4): 976-980.

相关文章 15

[1]	巩性军，吴树明，张供，李守先，庞昕焱. 无顶冠状静脉窦综合征的诊断和外科治疗[J]. 山东大学学报(医学版), 2209, 47(6): 129-.
[2]	孙文雄,吴日超,郑贤静,李丽, 张友忠. 宫颈血管周上皮样细胞肿瘤1例[J]. 山东大学学报 (医学版), 2022, 60(9): 125-128.
[3]	吴瑞芳,李长忠. 女性生育力保护的现状与进展[J]. 山东大学学报 (医学版), 2022, 60(9): 1-7.
[4]	王丽慧,高敏,孔北华. 子宫血管肉瘤2例报告并文献复习[J]. 山东大学学报 (医学版), 2022, 60(9): 108-112.
[5]	韩靖,贾春玲. 肺癌患者胸外手术前治疗牙周基础疾病对预防术后肺炎发生的效果评价[J]. 山东大学学报 (医学版), 2022, 60(9): 113-118.
[6]	王文静,刘博策,毕见海,霍然. 超声引导下平阳霉素联合聚桂醇硬化治疗94例囊性淋巴管畸形的疗效[J]. 山东大学学报 (医学版), 2022, 60(8): 72-78.
[7]	彭超,周应芳. 子宫腺肌病的药物治疗进展[J]. 山东大学学报 (医学版), 2022, 60(7): 20-25.
[8]	秦静,杨飞,陈谦,夏涵岱,刘延国,王秀问. 晚期驱动基因阴性、PD-L1表达阴性非鳞非小细胞肺癌一线治疗方案的网状Meta分析[J]. 山东大学学报 (医学版), 2022, 60(7): 74-82.
[9]	王福立,孙银萍,秦杰,荣建胜. DC-CIK细胞联合EGFR-TKI治疗35例老年晚期EGFR突变肺癌的效果[J]. 山东大学学报 (医学版), 2022, 60(7): 110-117.
[10]	王菊,高帅,范玉琛,王凯. 肝衰竭并发真菌感染综合治疗1例[J]. 山东大学学报 (医学版), 2022, 60(5): 125-128.
[11]	李献云,杨甫德. 自杀倾向的认知行为治疗[J]. 山东大学学报 (医学版), 2022, 60(4): 1-9.
[12]	孔昕欣,孙书珍,李倩,陈元,周爱华,王莉,姚秀俊. 抗H因子抗体阳性溶血尿毒综合征7例分析[J]. 山东大学学报 (医学版), 2022, 60(4): 82-86.
[13]	王静,刘粉,曾荣,黄思源,许长娟,梁子婷,董亮. 以胸膜病变为特征的IgG4相关性肺疾病1例[J]. 山东大学学报 (医学版), 2022, 60(3): 114-116.
[14]	薛美娟,石艳,邵琳琳,王琳,张昀,张阿敏. 遗传性血栓性血小板减少性紫癜1例并文献复习[J]. 山东大学学报 (医学版), 2022, 60(3): 121-124.
[15]	宋钰峰,宁豪,姚志刚,吴海虎,刘非凡,吕家驹. 肾上腺海绵状血管瘤临床及影像特征[J]. 山东大学学报 (医学版), 2022, 60(2): 37-42.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed